Blepharitis and Dry eyes in Aromatase Inhibitor Users Kiran Turaka, M.D. Kristin M. Hammersmith, M.D. Jennifer M. Nottage, M.D. Christopher J. Rapuano, M.D. Wills Eye Institute, Philadelphia PA The authors have no financial interest in the subject matter of this e-poster
13
Embed
Blepharitis and Dry eyes in Aromatase Inhibitor Users
Blepharitis and Dry eyes in Aromatase Inhibitor Users. Kiran Turaka, M.D. Kristin M. Hammersmith, M.D. Jennifer M. Nottage, M.D. Christopher J. Rapuano, M.D. Wills Eye Institute, Philadelphia PA The authors have no financial interest in the subject matter of this e-poster. Introduction . - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Blepharitis and Dry eyes in Aromatase
Inhibitor UsersKiran Turaka, M.D.Kristin M. Hammersmith, M.D.
Jennifer M. Nottage, M.D.Christopher J. Rapuano, M.D.
Wills Eye Institute, Philadelphia PAThe authors have no financial interest in the subject matter of this e-poster
* Few patients had more than one condition at presentation and a combination of topical medications
Presenting Ocular Symptoms*
Among the control population (65-69 years), dryness and irritation were found in 5.7% and 0.6% respectively. More than one symptom was found in 9.5% * Few patients had more than one
Summary at the Last follow-up No. of patients at the follow up: 11 (69%) No of patients lost to follow up: 5 (31%) No of patients on Anastrazole: 10 (91%) Mean ± SD follow-up: 14 ± 7.7 months